Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZNF217
REST API REST API
Homo sapiens
ZNF217 is differentially expressed in 279 experiments: 129 organism parts: cerebellum, placenta, ... (127 more);, 162 disease states: normal, prostate carcinoma, ... (160 more);, 74 cell types 291 cell lines 41 compound treatments and 65 other conditions.
Synonyms ZABC1
Orthologs ZNF217 (Gallus gallus)   ENSCING00000002573 (Ciona intestinalis)   ZNF217 (Danio rerio)   ZNF217 (Bos taurus)   Zfp217 (Mus musculus)   Zfp217 (Rattus norvegicus)   znf217 (Xenopus laevis)   ZNF217 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, histone deacetylase complex, intracellular, transcription, DNA-dependent, metal ion binding, nucleus, nucleoplasm, zinc ion binding, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
UniProt Accession O75362, Q9BZ31, A2A326, E7ET68, E1P5Y5
Search EB-eye ENSG00000171940
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-7224, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
MCF7
2
E-GEOD-5258, E-MTAB-37
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
SW480
1
2
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
BT474
1
2
E-MTAB-62, E-MTAB-37, E-MEXP-440
NCIH838
1
E-MTAB-37
285 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (37 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
whole blood
2
E-GEOD-3026, E-MTAB-25
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
chondrocyte
1
E-TABM-130
spermatocyte
1
E-TABM-130
astrocyte
1
E-GEOD-4483
68 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-MEXP-2280, ... (61 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-MEXP-2034, E-MTAB-62, E-MEXP-1327, E-GEOD-7307, E-TABM-26 ... (5 experiments)
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
acute lymphoblastic leukemia
2
E-GEOD-96, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
glioblastoma
2
E-GEOD-4290, E-GEOD-4412
Huntington's disease
1
2
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
156 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (25 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-20719, E-GEOD-5099, E-GEOD-5824, E-GEOD-412, E-MEXP-1958, ... (6 experiments)
LDL
1
E-GEOD-5741
AMP
1
E-MEXP-2285
unknown
1
E-GEOD-7307
5-fluorouridine
1
E-GEOD-995
TTA
1
E-MEXP-2590
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-20504, E-MEXP-1446, E-GEOD-19018, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-TABM-740, E-GEOD-2466, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-4525, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-3982 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.405 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM